Paul Vulto's Biography

Paul Vulto, Managing Director, MIMETAS

Paul Vulto is CEO and co-founder of MIMETAS. Under his guidance, MIMETAS developed into a multinational company with operations in Europe, US and Japan. MIMETAS currently works with the majority of top-50 pharma companies and counts over 85 co-workers. Paul is the inventor behind the OrganoPlate® platform and PhaseGuide technology of MIMETAS. Prior to founding MIMETAS, Paul worked for the high-tech company Silicon Biosystems in Bologna, the Institute for Microsystems Engineering (IMTEK) at the University of Freiburg and the Leiden Academic Centre for Drug Research, Leiden University. Paul holds a cum Laude masters degree in Electrical Engineering and a cum Laude PhD degree in Microsystems Engineering.

96 Kidney Tubules On-a-Chip For Real-Time Toxicity Testing

Thursday, 7 July 2016 at 15:00

Add to Calendar ▼2016-07-07 15:00:002016-07-07 16:00:00Europe/London96 Kidney Tubules On-a-Chip For Real-Time Toxicity TestingSELECTBIOenquiries@selectbiosciences.com

Drug toxicity remains a major issue in drug discovery and stresses the need for better predictive models. Here, we describe the development of a perfused renal proximal tubule cell (RPTC) model in Mimetas’ OrganoPlates™to predict kidney toxicity. The OrganoPlate™ is a microfluidic platform, which enables high-throughput culture of boundary tissues in miniaturized organ models. In OrganoPlates™, extracellular matrix (ECM) gels can be freely patterned in microchambers through the use of PhaseGuide™ technology. We demonstrate 96 perfused RPTCs on one OrganoPlate on which toxicity effects can be monitored in real-time. The model capitulates crucial aspects of the proximal tubule, including leak-tightness, apical-basal polarization and expression of a range of crucial transporters.

Add to Calendar ▼2016-07-07 00:00:002016-07-08 00:00:00Europe/LondonOrgan-on-a-Chip and Body-on-a-Chip: In Vitro Systems Mimicking In Vivo FunctionsSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors